Clinical context
In glaucoma, intraocular pressure reduction is important but remains a surrogate outcome. Clinical value also depends on preservation of the visual field and optic nerve, safety, the need for additional medication or surgery, and treatment adherence. Target pressure is individualized, so the same numerical change can carry different meaning at different disease stages and rates of progression.
What was studied
This retrospective study included 880 eyes treated with phacoemulsification and Tanito microhook trabeculotomy: 761 had primary open-angle and 119 exfoliation glaucoma. Outcomes were stratified by incision below 6 or at least 6 clock hours, severity and medication burden. AAO MIGS success required one fewer medication without IOP increase or at least 20% pressure reduction to 21 mmHg or lower, without further surgery, hypotony or loss of light perception.
How the evidence was produced
A cohort study describes how outcomes are associated with an exposure or treatment in an observed clinical population. This design is useful for routine practice, uncommon events and longer follow-up, but it remains vulnerable to confounding by indication, baseline risk differences and missing data. An association should not automatically be interpreted as a causal effect.
How to interpret the result
This large series suggests that phaco‑TMH can lower pressure by about 4 mmHg and modestly reduce medication burden over two years. Forty-one percent failed the composite criterion. Lack of benefit from an incision of at least 6 hours does not prove identical techniques because extent may reflect anatomy and preference. Wider treatment is not automatically more effective; baseline pressure, medications, glaucoma type and target remain important.
The result should be understood as an estimate for the population studied, not a promise of an individual outcome. Statistical and clinical significance, absolute and relative effects, and prespecified and exploratory analyses should be distinguished. When several endpoints or subgroups are reported, the prespecified primary endpoint for which the study was designed usually provides the most reliable inference.
Clinical applicability
The findings can inform discussions about treatment sequence and burden. Before changing management, compare the study population with the patient in front of you, including glaucoma stage, baseline pressure, previous treatment, angle anatomy and rate of field loss. A pressure measurement does not replace structural and functional follow-up.
Limitations
The study was retrospective and nonrandomized, with confounding by indication. Eyes spanned years and stages, while the endpoint combines pressure and medication change. Fellow-eye dependence may matter. Author relationships with the microhook developer require review, although the company had no study role. Check follow-up counts, missing data, complications, reoperations, baseline differences, medication rules and outcomes by glaucoma type.
Beyond the limitations acknowledged by the authors, confidence is affected by sample size, follow-up duration, missing data, choice of comparator and relevance of the outcomes to routine care. Uncommon complications may remain undetected even in a well-conducted study. External validity is reduced when participants, equipment or investigator expertise differ substantially from everyday settings.
What to verify in the source
In the full paper, verify the protocol, eligibility criteria, baseline group characteristics, primary endpoint definition, confidence intervals, adverse events and losses to follow-up. Funding, conflicts of interest, trial registration and consistency between the published analysis and the original plan deserve separate attention. The DOI or source link below provides access to the primary publication for this check.